Pharmacologic management of metabolic and alcohol-associated liver disease
Mangesh Pagadala, Sajid Jalil, Nicholas Dunn, Ashwani K Singal · 2026
Read Pharmacologic management of metabolic and alcohol-associated liver disease by Mangesh Pagadala, Sajid Jalil, Nicholas Dunn, Ashwani K Singal (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13455180.txt.
Description
Mangesh Pagadala, Sajid Jalil, Nicholas Dunn, and Ashwani K. Singal review, in 2026, drug care for a liver condition where metabolic harm and alcohol act together. The overlap condition, called MetALD, scars the liver faster than either cause alone. Trials have largely shut such patients out, leaving doctors to borrow evidence from neighboring diseases.
Current care attacks both fronts at once, with alcohol control first when drinking continues. The review surveys liver drugs proven in fatty liver disease, including incretin agents, hormone mimics, and a thyroid-linked drug, for their possible fit here. Some may also curb drinking through brain reward routes. Proven alcohol medicines such as acamprosate and naltrexone, paired with counseling, anchor the other front. The authors close by sketching how dedicated trials for this overlap group should be designed.
Catalog record
| CREATOR | Mangesh Pagadala, Sajid Jalil, Nicholas Dunn, Ashwani K Singal |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58207 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |